Literature DB >> 24795154

Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [(11)C]ABP688 study.

M S Milella1, L Marengo1, K Larcher2, A Fotros1, A Dagher2, P Rosa-Neto3, C Benkelfat4, M Leyton5.   

Abstract

Cocaine self-administration decreases type 5 metabotropic glutamate receptor (mGluR5) tissue concentrations in laboratory rats during early abstinence. These changes are thought to influence the drug's reinforcing properties and the ability of drug-related cues to induce relapse. Here, our goal was to measure brain regional mGluR5 availability in recently abstinent cocaine dependent humans. Participants meeting DSM-IV diagnostic criteria for current cocaine dependence (n=9) were recruited from the general population. mGluR5 availability (binding potential, non-displaceable; BPND) was measured with high-resolution positron emission tomography (PET HRRT) and [(11)C]ABP688. Compared to age- and sex-matched healthy controls (n=9), cocaine dependent subjects showed significantly lower BPND values in the ventral (bilateral: -28.2%, p=0.011), associative (right: -21.4%, p=0.043), and sensorimotor striatum (bilateral: -21.7%, p=0.045), amygdala (left: -26%, p=0.046) and insula (right: -23.3%, p=0.041). Among the cocaine users, receptor availabilities were related to abstinence (range: 2 to 14days). The longer the duration of abstinence, the lower the BPND values in the sensorimotor striatum (r=-0.71, p=0.034), left amygdala (r=-0.73, p=0.026) and right insula (r=-0.67, p=0.046). Compared to healthy controls, BPND values were significantly reduced in those who tested negative for cocaine on the PET test session in the ventral (p=0.018) and sensorimotor striatum (p=0.017), left amygdala (p=0.008), and right insula (p=0.029), but not in those who tested positive. Together, these results provide evidence of time-related mGluR5 alterations in striatal and limbic regions in humans during early cocaine abstinence.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abstinence; Addiction; Glutamate; Positron emission tomography; Relapse; Striatum

Mesh:

Substances:

Year:  2014        PMID: 24795154     DOI: 10.1016/j.neuroimage.2014.04.061

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  25 in total

1.  Comparative assessment of parametric neuroreceptor mapping approaches based on the simplified reference tissue model using [¹¹C]ABP688 PET.

Authors:  Seongho Seo; Su J Kim; Yu K Kim; Jee-Young Lee; Jae M Jeong; Dong S Lee; Jae S Lee
Journal:  J Cereb Blood Flow Metab       Date:  2015-08-05       Impact factor: 6.200

2.  Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence.

Authors:  Sophie E Holmes; Matthew J Girgenti; Margaret T Davis; Robert H Pietrzak; Nicole DellaGioia; Nabeel Nabulsi; David Matuskey; Steven Southwick; Ronald S Duman; Richard E Carson; John H Krystal; Irina Esterlis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

3.  Test-retest reproducibility of the metabotropic glutamate receptor 5 ligand [¹⁸F]FPEB with bolus plus constant infusion in humans.

Authors:  Eunkyung Park; Jenna M Sullivan; Beata Planeta; Jean-Dominique Gallezot; Keunpoong Lim; Shu-Fei Lin; Jim Ropchan; Timothy J McCarthy; Yu-Shin Ding; Evan D Morris; Wendol A Williams; Yiyun Huang; Richard E Carson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-05       Impact factor: 9.236

4.  A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5.

Authors:  Geoffrey Warnock; Michael Sommerauer; Linjing Mu; Gloria Pla Gonzalez; Susanne Geistlich; Valerie Treyer; Roger Schibli; Alfred Buck; Stefanie D Krämer; Simon M Ametamey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-27       Impact factor: 9.236

Review 5.  Neuroimaging markers of glutamatergic and GABAergic systems in drug addiction: Relationships to resting-state functional connectivity.

Authors:  Scott J Moeller; Edythe D London; Georg Northoff
Journal:  Neurosci Biobehav Rev       Date:  2015-12-01       Impact factor: 8.989

Review 6.  Metabotropic glutamate receptor 5 as a potential target for smoking cessation.

Authors:  Cristiano Chiamulera; Claudio Marcello Marzo; David J K Balfour
Journal:  Psychopharmacology (Berl)       Date:  2016-11-16       Impact factor: 4.530

7.  Effect of (Z)-isomer content on [11C]ABP688 binding potential in humans.

Authors:  Kelly Smart; Sylvia M L Cox; Alexey Kostikov; Aliaksandr Shalai; Stephanie G Scala; Maria Tippler; Natalia Jaworska; Michel Boivin; Jean R Séguin; Chawki Benkelfat; Marco Leyton
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-03       Impact factor: 9.236

Review 8.  Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging.

Authors:  Rajapillai L I Pillai; Dnyanesh N Tipre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-07       Impact factor: 9.236

Review 9.  Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies.

Authors:  Irina Esterlis; Sophie E Holmes; Priya Sharma; John H Krystal; Christine DeLorenzo
Journal:  Biol Psychiatry       Date:  2017-09-19       Impact factor: 13.382

10.  Dysregulation of Decision Making Related to Metabotropic Glutamate 5, but Not Midbrain D3, Receptor Availability Following Cocaine Self-administration in Rats.

Authors:  Stephanie M Groman; Ansel T Hillmer; Heather Liu; Krista Fowles; Daniel Holden; Evan D Morris; Daeyeol Lee; Jane R Taylor
Journal:  Biol Psychiatry       Date:  2020-06-29       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.